Diabetes and Metabolism Journal

Korean Diabetes Association (대한당뇨병학회)
권호 표지
DOI QR코드

DOI QR Code

Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases

  • Han, Eugene (Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine) ;
  • Lee, Yong-ho (Graduate School, Yonsei University College of Medicine)
  • Received : 2017.10.12
  • Accepted : 2017.11.12
  • Published : 2017.12.15
⟨ Previous Next ⟩

Abstract

As the number of individuals with non-alcoholic fatty liver disease (NAFLD) has increased, the influence of NAFLD on other metabolic diseases has been highlighted. Accumulating epidemiologic evidence indicates that NAFLD not only affects the liver but also increases the risk of extra-hepatic diseases such as type 2 diabetes mellitus, metabolic syndrome, dyslipidemia, hypertension, cardiovascular or cerebrovascular diseases, and chronic kidney disease. Non-alcoholic steatohepatitis, an advanced type of NAFLD, can aggravate these inter-organ relationships and lead to poorer outcomes. NAFLD induces insulin resistance and exacerbates systemic chronic inflammation and oxidative stress, which leads to organ dysfunction in extra-hepatic tissues. Although more research is needed to identify the pathophysiological mechanisms and causal relationship between NAFLD and cardiometabolic and renal diseases, screening for heart, brain, and kidney diseases, risk assessment for diabetes, and a multidisciplinary approach for managing these patients should be highly encouraged.

Keywords

Acknowledgement

Supported by : Ministry of Health and Welfare

References

  1. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-8. https://doi.org/10.1016/S0140-6736(06)69703-1
  2. Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J 2011;35:561-6. https://doi.org/10.4093/dmj.2011.35.6.561
  3. Farrell GC, Wong VW, Chitturi S. NAFLD in Asia: as common and important as in the West. Nat Rev Gastroenterol Hepatol 2013;10:307-18. https://doi.org/10.1038/nrgastro.2013.34
  4. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. https://doi.org/10.1002/hep.25762
  5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84. https://doi.org/10.1002/hep.28431
  6. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524-30. https://doi.org/10.1016/j.cgh.2011.03.020
  7. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67:862-73. https://doi.org/10.1016/j.jhep.2017.06.003
  8. Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, Ratziu V. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 2017; 46:856-63. https://doi.org/10.1111/apt.14261
  9. Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, Charlton M. Changes in the prevalence of hepatitis c virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 2017; 152:1090-9. https://doi.org/10.1053/j.gastro.2017.01.003
  10. Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, Kang ES, Han KH, Lee HC, Cha BS. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). J Hepatol 2015;63: 486-93. https://doi.org/10.1016/j.jhep.2015.02.051
  11. Lee YH, Kim SU, Song K, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Han KH. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: nationwide surveys (KNHANES 2008-2011). Hepatology 2016;63:776-86. https://doi.org/10.1002/hep.28376
  12. Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, Cha BS, Lee HC, Balkau B, Lee WY, Kim DJ. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One 2014;9:e107584. https://doi.org/10.1371/journal.pone.0107584
  13. Lee MK, Rhee EJ, Kim MC, Moon BS, Lee JI, Song YS, Han EN, Lee HS, Son Y, Park SE, Park CY, Oh KW, Park SW, Lee WY. Metabolic health is more important than obesity in the development of nonalcoholic fatty liver disease: a 4-year retrospective study. Endocrinol Metab (Seoul) 2015;30:522-30. https://doi.org/10.3803/EnM.2015.30.4.522
  14. Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013;57:1378-83. https://doi.org/10.1002/hep.26183
  15. Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, Park SW, Kim SW. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011;34:727-9. https://doi.org/10.2337/dc10-1991
  16. Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 2013;108:1861-8. https://doi.org/10.1038/ajg.2013.349
  17. Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010;25:352-6. https://doi.org/10.1111/j.1440-1746.2009.05998.x
  18. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402.
  19. Zhang QQ, Lu LG. Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol 2015;3:78-84. https://doi.org/10.14218/JCTH.2014.00037
  20. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50. https://doi.org/10.1056/NEJMra0912063
  21. Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 2011;56:3439-49. https://doi.org/10.1007/s10620-011-1767-y
  22. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis2012;32:22-9. https://doi.org/10.1055/s-0032-1306423
  23. Corey KE, Vuppalanchi R, Wilson LA, Cummings OW, Chalasani N; NASH CRN. NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. Aliment Pharmacol Ther 2015;41:301-9. https://doi.org/10.1111/apt.13035
  24. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009;104:861-7. https://doi.org/10.1038/ajg.2009.67
  25. Bril F, Sninsky JJ, Baca AM, Superko HR, Portillo Sanchez P, Biernacki D, Maximos M, Lomonaco R, Orsak B, Suman A, Weber MH, McPhaul MJ, Cusi K. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab 2016;101:644-52. https://doi.org/10.1210/jc.2015-3111
  26. Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol 2014;29:1926-31. https://doi.org/10.1111/jgh.12643
  27. Huh JH, Ahn SV, Koh SB, Choi E, Kim JY, Sung KC, Kim EJ, Park JB. A prospective study of fatty liver index and incident hypertension: the KoGES-ARIRANG Study. PLoS One 2015; 10:e0143560. https://doi.org/10.1371/journal.pone.0143560
  28. Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol 2014;60:1040-5. https://doi.org/10.1016/j.jhep.2014.01.009
  29. Lopez-Suarez A, Guerrero JM, Elvira-Gonzalez J, Beltran-Robles M, Canas-Hormigo F, Bascunana-Quirell A. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol 2011;23:1011-7.
  30. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006;29:1325-30. https://doi.org/10.2337/dc06-0135
  31. Kim J, Lee DY, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation. PLoS One 2017;12:e0180118. https://doi.org/10.1371/journal.pone.0180118
  32. Sinn DH, Kang D, Chang Y, Ryu S, Gu S, Kim H, Seong D, Cho SJ, Yi BK, Park HD, Paik SW, Song YB, Lazo M, Lima JA, Guallar E, Cho J, Gwak GY. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut 2017;66:323-9. https://doi.org/10.1136/gutjnl-2016-311854
  33. Loria P, Lonardo A, Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond) 2008;115:1-12. https://doi.org/10.1042/CS20070311
  34. Luna-Luna M, Medina-Urrutia A, Vargas-Alarcon G, Coss-Rovirosa F, Vargas-Barron J, Perez-Mendez O. Adipose tissue in metabolic syndrome: onset and progression of atherosclerosis. Arch Med Res 2015;46:392-407. https://doi.org/10.1016/j.arcmed.2015.05.007
  35. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42:473-80. https://doi.org/10.1002/hep.20781
  36. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21. https://doi.org/10.1053/j.gastro.2005.04.014
  37. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44: 865-73. https://doi.org/10.1002/hep.21327
  38. Lee JI, Kim MC, Moon BS, Song YS, Han EN, Lee HS, Son Y, Kim J, Han EJ, Park HJ, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. The relationship between 10-year cardiovascular risk calculated using the pooled cohort equation and the severity of non-alcoholic fatty liver disease. Endocrinol Metab (Seoul) 2016;31:86-92. https://doi.org/10.3803/EnM.2016.31.1.86
  39. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016;65:589-600. https://doi.org/10.1016/j.jhep.2016.05.013
  40. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017;66:1138-53. https://doi.org/10.1136/gutjnl-2017-313884
  41. Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, Melzer E, Orr A, Caspi A, Malnick S. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006;40:949-55. https://doi.org/10.1097/01.mcg.0000225668.53673.e6
  42. Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic D, MacGowan GA, Anstee QM, Taylor R, Day CP, Trenell MI. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol 2013;58:757-62. https://doi.org/10.1016/j.jhep.2012.11.015
  43. Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, Ragogna F, Canu T, Scifo P, Del Maschio A, Luzi L. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008;47:51-8.
  44. Rijzewijk LJ, Jonker JT, van der Meer RW, Lubberink M, de Jong HW, Romijn JA, Bax JJ, de Roos A, Heine RJ, Twisk JW, Windhorst AD, Lammertsma AA, Smit JW, Diamant M, Lamb HJ. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010;56:225-33. https://doi.org/10.1016/j.jacc.2010.02.049
  45. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004;109:2191-6. https://doi.org/10.1161/01.CIR.0000127959.28627.F8
  46. Hung CS, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC, Chiu HM, Lin HJ, Ho YL, Yang WS, Wu MS, Chen MF. Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J Am Heart Assoc 2015;4:e001820.
  47. Mantovani A, Rigamonti A, Bonapace S, Bolzan B, Pernigo M, Morani G, Franceschini L, Bergamini C, Bertolini L, Valbusa F, Rigolon R, Pichiri I, Zoppini G, Bonora E, Violi F, Targher G. nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring. Diabetes Care 2016;39:1416-23. https://doi.org/10.2337/dc16-0091
  48. Karajamaki AJ, Patsi OP, Savolainen M, Kesaniemi YA, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS One 2015;10:e0142937. https://doi.org/10.1371/journal.pone.0142937
  49. Ying I, Saposnik G, Vermeulen MJ, Leung A, Ray JG. Nonalcoholic fatty liver disease and acute ischemic stroke. Epidemiology 2011;22:129-30. https://doi.org/10.1097/EDE.0b013e3181feb50a
  50. Abdeldyem SM, Goda T, Khodeir SA, Abou Saif S, Abd-Elsalam S. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J Clin Lipidol 2017;11:915-9. https://doi.org/10.1016/j.jacl.2017.04.115
  51. Kim SU, Song D, Heo JH, Yoo J, Kim BK, Park JY, Kim DY, Ahn SH, Kim KJ, Han KH, Kim YD. Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. Atherosclerosis 2017;260:156-62. https://doi.org/10.1016/j.atherosclerosis.2017.02.005
  52. Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol 2017;13:297-310. https://doi.org/10.1038/nrneph.2017.16
  53. Yilmaz Y, Alahdab YO, Yonal O, Kurt R, Kedrah AE, Celikel CA, Ozdogan O, Duman D, Imeryuz N, Avsar E, Kalayci C. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism 2010;59:1327-30. https://doi.org/10.1016/j.metabol.2009.12.012
  54. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010;5:2166-71. https://doi.org/10.2215/CJN.05050610
  55. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagstrom H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Haflithadottir S, Bjornsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Volzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680. https://doi.org/10.1371/journal.pmed.1001680
  56. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357-65. https://doi.org/10.1002/hep.26156
  57. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-73. https://doi.org/10.1001/jama.2015.5370
  58. Tahara N, Yamagishi S, Takeuchi M, Honda A, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, Ishibashi M, Hayabuchi N, Matsui T, Imaizumi T. Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care 2012;35:2618-25. https://doi.org/10.2337/dc12-0087
  59. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 2016; 13:412-25. https://doi.org/10.1038/nrgastro.2016.85
  60. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013;368:1575-84. https://doi.org/10.1056/NEJMoa1109400

Cited by

  1. Capybara Oil Improves Hepatic Mitochondrial Dysfunction, Steatosis, and Inflammation in a Murine Model of Nonalcoholic Fatty Liver Disease vol.2018, pp.None, 2017, https://doi.org/10.1155/2018/4956079
  2. STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia vol.38, pp.8, 2018, https://doi.org/10.1161/atvbaha.118.311241
  3. Organ-Specific Mechanisms of Transendothelial Neutrophil Migration in the Lung, Liver, Kidney, and Aorta vol.9, pp.None, 2018, https://doi.org/10.3389/fimmu.2018.02739
  4. Obesity induced alterations in redox homeostasis and oxidative stress are present from an early age vol.13, pp.1, 2017, https://doi.org/10.1371/journal.pone.0191547
  5. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice vol.19, pp.1, 2017, https://doi.org/10.3390/ijms19010137
  6. Persistently Increased Resting Energy Expenditure Predicts Short-Term Mortality in Patients with Acute-on-Chronic Liver Failure vol.73, pp.1, 2017, https://doi.org/10.1159/000487604
  7. Association of sex hormone-binding globulin with nonalcoholic fatty liver disease in Chinese adults vol.15, pp.1, 2018, https://doi.org/10.1186/s12986-018-0313-8
  8. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis vol.43, pp.1, 2017, https://doi.org/10.4093/dmj.2019.0011
  9. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment vol.43, pp.2, 2019, https://doi.org/10.4093/dmj.2019.0034
  10. Chicken Protein Hydrolysates Have Anti-Inflammatory Effects on High-Fat Diet Induced Obesity in Mice vol.6, pp.1, 2017, https://doi.org/10.3390/medicines6010005
  11. Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment vol.35, pp.7, 2017, https://doi.org/10.1080/03007995.2019.1589152
  12. Association Between Nonalcoholic Fatty Liver Disease and Future Deterioration of Metabolic Health: A Cohort Study vol.27, pp.8, 2017, https://doi.org/10.1002/oby.22536
  13. Subfornical organ insulin receptors tonically modulate cardiovascular and metabolic function vol.51, pp.8, 2017, https://doi.org/10.1152/physiolgenomics.00021.2019
  14. Progress in the Study of the Pathogenesis of Chronic Kidney Disease Associated with Nonalcoholic Fatty Liver Disease vol.9, pp.9, 2017, https://doi.org/10.12677/acm.2019.99165
  15. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients vol.56, pp.11, 2017, https://doi.org/10.1007/s00592-019-01374-x
  16. Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model vol.13, pp.1, 2019, https://doi.org/10.1186/s13036-019-0198-8
  17. Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes vol.99, pp.33, 2017, https://doi.org/10.1097/md.0000000000021038
  18. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association vol.44, pp.3, 2017, https://doi.org/10.4093/dmj.2020.0010
  19. Sarcopenia: an emerging risk factor for non-alcoholic fatty liver disease vol.14, pp.1, 2017, https://doi.org/10.1007/s12072-019-09999-4
  20. Association Between Serum Bilirubin and the Progression of Carotid Atherosclerosis in Type 2 Diabetes vol.9, pp.1, 2017, https://doi.org/10.12997/jla.2020.9.1.195
  21. Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial vol.9, pp.1, 2017, https://doi.org/10.3390/jcm9010259
  22. Correlation Between Non-Alcoholic Fatty Liver and Chronic Kidney Disease vol.13, pp.None, 2017, https://doi.org/10.2174/1874303x02013010001
  23. Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38) vol.29, pp.2, 2020, https://doi.org/10.7570/jomes20018
  24. Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation vol.1866, pp.6, 2017, https://doi.org/10.1016/j.bbadis.2020.165741
  25. A preliminary report about the detection of ventricular repolarisation in patients with non-alcoholic fatty liver disease vol.15, pp.4, 2017, https://doi.org/10.1016/j.jtumed.2020.05.003
  26. Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview vol.10, pp.11, 2017, https://doi.org/10.3390/metabo10110465
  27. Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west? vol.20, pp.None, 2017, https://doi.org/10.1186/s12876-020-01278-z
  28. Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study vol.19, pp.None, 2017, https://doi.org/10.1186/s12933-020-01064-x
  29. Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease vol.34, pp.3, 2021, https://doi.org/10.1007/s40620-020-00751-y
  30. Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease vol.45, pp.5, 2017, https://doi.org/10.4093/dmj.2020.0118